MX2022015800A - Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. - Google Patents
Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.Info
- Publication number
- MX2022015800A MX2022015800A MX2022015800A MX2022015800A MX2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A MX 2022015800 A MX2022015800 A MX 2022015800A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- rho kinase
- preferred
- kinase inhibitors
- vascular dementia
- Prior art date
Links
- 239000003590 rho kinase inhibitor Substances 0.000 title abstract 3
- 201000004810 Vascular dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002435 fasudil Drugs 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039141P | 2020-06-15 | 2020-06-15 | |
| US202063046173P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/012590 WO2021257122A1 (en) | 2020-06-15 | 2021-01-08 | Methods of using rho kinase inhibitors to treat vascular dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015800A true MX2022015800A (es) | 2023-01-24 |
Family
ID=79268240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015800A MX2022015800A (es) | 2020-06-15 | 2021-01-08 | Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230285409A1 (enExample) |
| EP (1) | EP4164652A4 (enExample) |
| JP (1) | JP2023530120A (enExample) |
| CN (1) | CN116249532A (enExample) |
| CA (1) | CA3180411A1 (enExample) |
| MX (1) | MX2022015800A (enExample) |
| WO (1) | WO2021257122A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| WO2024243197A2 (en) * | 2023-05-24 | 2024-11-28 | Woolsey Pharmaceuticals, Inc. | Method of treating patients with notch3 mutations |
| WO2025024104A2 (en) * | 2023-07-06 | 2025-01-30 | Woolsey Pharmaceuticals, Inc. | Method for reducing caregiver burden associated with alzheimer's disease |
| WO2025101834A1 (en) * | 2023-11-10 | 2025-05-15 | Woolsey Pharmaceuticals, Inc. | Methods of treating sporadic cerebral small vessel disease |
| CN119954776A (zh) * | 2025-03-03 | 2025-05-09 | 中国药科大学 | 一种法舒地尔二氯乙酸盐的制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117896A1 (de) * | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| EP2061314A4 (en) * | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| US20110237600A1 (en) * | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| US20140199318A1 (en) * | 2011-08-12 | 2014-07-17 | Max-Del-Bruck-Centrum Fur Molekulare Medizin | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia |
| WO2013066151A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
| EP2961405A4 (en) * | 2012-12-14 | 2017-03-29 | The Brigham and Women's Hospital, Inc. | Methods and assays relating to macrophage differentiation |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| MX2022009479A (es) * | 2020-02-10 | 2022-08-22 | Woolsey Pharmaceuticals Inc | Metodos para tratar afeccion pseudobulbar y otras alteraciones emocionales. |
-
2021
- 2021-01-08 WO PCT/US2021/012590 patent/WO2021257122A1/en not_active Ceased
- 2021-01-08 MX MX2022015800A patent/MX2022015800A/es unknown
- 2021-01-08 EP EP21824978.7A patent/EP4164652A4/en not_active Withdrawn
- 2021-01-08 US US18/001,514 patent/US20230285409A1/en not_active Abandoned
- 2021-01-08 CN CN202180059786.2A patent/CN116249532A/zh active Pending
- 2021-01-08 JP JP2022576866A patent/JP2023530120A/ja active Pending
- 2021-01-08 CA CA3180411A patent/CA3180411A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230285409A1 (en) | 2023-09-14 |
| EP4164652A4 (en) | 2024-07-10 |
| WO2021257122A1 (en) | 2021-12-23 |
| CA3180411A1 (en) | 2021-12-23 |
| EP4164652A1 (en) | 2023-04-19 |
| JP2023530120A (ja) | 2023-07-13 |
| CN116249532A (zh) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012957A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| Schnider et al. | Long‐term outcome of patients with headache and drug abuse after inpatient withdrawal: five‐year follow‐up | |
| MX2024000357A (es) | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| Estemalik et al. | Preventive treatment in migraine and the new US guidelines | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| Kontaxakis et al. | Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review | |
| Jenkins et al. | The evidence for symptomatic treatments in amyotrophic lateral sclerosis | |
| MXPA05003550A (es) | Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos. | |
| NO20065676L (no) | Forebyggelse av arteriell restenose med aktive vitamin D forbindelser. | |
| DE60027431D1 (de) | Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| Saag et al. | Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo‐controlled study | |
| ZA202210560B (en) | Inhibiting creb binding protein (cbp) | |
| BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| Pitt et al. | A double‐blind randomized placebo‐controlled trial of oral indoramin to treat chronic anal fissure | |
| JP2023523706A5 (enExample) | ||
| MX2025000469A (es) | Métodos y sistemas para el tratamiento de enfermedades mediante el uso de un inhibidor de la vía de señalización atr/chk1. | |
| Prasko et al. | Augmentation of antidepressants with bright light therapy in patients with comorbid depression and borderline personality disorder | |
| Tadros et al. | Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications | |
| ZA202307921B (en) | Combination of raf inhibitor and mek inhibitor |